Brokerages Set Lantheus Holdings, Inc. (NASDAQ:LNTH) PT at $82.17

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been given a consensus rating of “Moderate Buy” by the eleven brokerages that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $86.1429.

Several equities analysts have commented on LNTH shares. Truist Financial increased their target price on shares of Lantheus from $82.00 to $89.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Jefferies Financial Group reiterated a “buy” rating and set a $110.00 price target on shares of Lantheus in a research note on Tuesday. JonesTrading downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Finally, Mizuho boosted their target price on Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a report on Friday, February 27th.

Lantheus Price Performance

NASDAQ LNTH opened at $80.45 on Friday. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $5.24 billion, a PE ratio of 23.87 and a beta of -0.11. The company has a 50 day moving average price of $70.93 and a two-hundred day moving average price of $62.16. Lantheus has a 12-month low of $47.25 and a 12-month high of $108.91.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, topping the consensus estimate of $1.17 by $0.50. The company had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. Lantheus’s quarterly revenue was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities analysts predict that Lantheus will post 6.01 earnings per share for the current fiscal year.

Institutional Trading of Lantheus

Institutional investors and hedge funds have recently modified their holdings of the company. Hantz Financial Services Inc. grew its stake in Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new position in Lantheus during the 2nd quarter worth $26,000. First Horizon Corp acquired a new position in Lantheus during the 3rd quarter worth $26,000. Smartleaf Asset Management LLC boosted its holdings in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 197 shares during the period. Finally, Parallel Advisors LLC grew its position in shares of Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 298 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.